Research programme: chronic pain therapeutics - New River Pharmaceuticals

Drug Profile

Research programme: chronic pain therapeutics - New River Pharmaceuticals

Alternative Names: NRP 369; Oxycodone prodrugs - New River Pharmaceuticals

Latest Information Update: 10 Mar 2008

Price : $50

At a glance

  • Originator New River Pharmaceuticals
  • Class Morphine derivatives
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 21 Feb 2008 Discontinued - Preclinical for Pain in USA (PO)
  • 24 Mar 2005 NRP 369 is available for licensing (http://www.nrpharma.com)
  • 23 Jun 2004 Preclinical trials in Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top